Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of 0.00% is 100% above its 5-year average of -103072.64%, around the middle of its 5-year range (-366090.91%–193577.27%).
100.00% above its 12-month average of -202.24%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1011.21%.
OPERATING MARGIN
0.00%
OPERATING MARGIN AVG TTM
-202.24%
OPERATING MARGIN AVG 3Y
-112.36%
OPERATING MARGIN AVG 5Y
-103072.64%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+100.00%
CURRENT VS 3Y AVG
+100.00%
CURRENT VS 5Y AVG
+100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 748 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Allogene Therapeutics, Inc.
Market Cap
$502.20M
Operating Margin
0.00%
TTM Avg
-202.24%
3Y Avg
-112.36%
5Y Avg
-103072.64%
Market Cap
$508.33M
Operating Margin
-46.01%
TTM Avg
-85.84%
3Y Avg
-83.08%
5Y Avg
-67.71%
Market Cap
$495.23M
Operating Margin
-7.33%
TTM Avg
-12.79%
3Y Avg
-23.47%
5Y Avg
-68.20%
Market Cap
$495.09M
Operating Margin
0.00%
TTM Avg
-5335.57%
3Y Avg
-2667.78%
5Y Avg
-1778.52%
Market Cap
$486.60M
Operating Margin
13.16%
TTM Avg
14.88%
3Y Avg
13.50%
5Y Avg
6.84%
Market Cap
$518.16M
Operating Margin
-1407.52%
TTM Avg
-703.76%
3Y Avg
-114341.22%
5Y Avg
-77223.74%
Market Cap
$519.25M
Operating Margin
-230460.98%
TTM Avg
-373160.49%
3Y Avg
-159952.53%
5Y Avg
-107112.87%
Market Cap
$523.60M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$479.07M
Operating Margin
-43.75%
TTM Avg
-69.37%
3Y Avg
-212.63%
5Y Avg
-278.07%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | $502.20M | 0.00% | -202.24% | -112.36% | -103072.64% |
| 908 Devices Inc. (MASS)vs › | $508.33M | -46.01% | -85.84% | -83.08% | -67.71% |
| Evolus, Inc. (EOLS)vs › | $495.23M | -7.33% | -12.79% | -23.47% | -68.20% |
| Oculis Holding AG (OCS)vs › | $495.09M | 0.00% | -5335.57% | -2667.78% | -1778.52% |
| Puma Biotechnology, Inc. (PBYI)vs › | $486.60M | 13.16% | 14.88% | 13.50% | 6.84% |
| Crescent Biopharma, Inc. (CBIO)vs › | $518.16M | -1407.52% | -703.76% | -114341.22% | -77223.74% |
| Altimmune, Inc. (ALT)vs › | $519.25M | -230460.98% | -373160.49% | -159952.53% | -107112.87% |
| Monopar Therapeutics Inc. (MNPR)vs › | $523.60M | 0.00% | 0.00% | 0.00% | 0.00% |
| Arvinas, Inc. (ARVN)vs › | $479.07M | -43.75% | -69.37% | -212.63% | -278.07% |
| Immix Biopharma, Inc. (IMMX)vs › | $527.94M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
0.0%
Operating Margin
0.0%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -1011.21% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | -315927.27% |
| 2023-12-31 | 193577.27% |
| 2023-09-30 | -286345.45% |
| 2023-06-30 | -366090.91% |
| 2023-03-31 | -330306.67% |
| 2022-12-31 | -205051.06% |
| 2022-09-30 | -168344.90% |
| 2022-06-30 | -89062.79% |
| 2022-03-31 | -131134.43% |
| 2021-12-31 | -144888.24% |
| 2021-09-30 | -158510.20% |
| 2021-06-30 | -161429.55% |
| 2021-03-31 | -86.58% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
